In a rare Chapter 11 outcome, InVivo Therapeutics shareholders receive a final distribution of ~$0.60 per share, exceeding estimates, after all creditor claims were satisfied.
The final act of the InVivo Therapeutics Holdings story is now being written. In a departure from the typical outcome in bankruptcy proceedings, where equity holders often face a total loss, shareholders of this former biotechnology firm are set to receive a final distribution that exceeds initial projections. The recent filing of a final report brings the Chapter 11 case to a definitive close.
A Rare Outcome for Equity Holders
For a company navigating Chapter 11 bankruptcy, the complete satisfaction of all creditor claims is an uncommon…